SLC18A2 and Parkinson disease: We report two cases of VMAT-2 inhibitors induced Parkinsonism of which one of them is a man in whom we propose that the underlying Parkinson’s disease (based on decreased uptake in right putamen and clinical presentation) was unmasked secondary to newly introduced dopamine-depleting medication.